Summit Therapeutics Total Assets 2011-2026 | SMMT

Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.

Main categories of assets
Current assets (used within one year):

Cash and cash equivalents
Accounts receivable (amounts owed by customers)
Inventory of goods, raw materials, and supplies
Short-term investments

Non-current assets (used for more than one year):

Fixed assets (buildings, machinery, equipment)
Intangible assets (brands, patents, software)
Long-term investments
Goodwill (reputational value from mergers)

Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.

Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.

Annual Total Assets Summit Therapeutics

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
751 M	436 M	203 M	664 M	113 M	102 M	78.4 M	76.4 M	47 M	35.7 M	29.2 M	10.9 M	6.91 M	6.12 M	8.06 M

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
751 M	6.12 M	171 M

Quarterly Total Assets Summit Therapeutics

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
262 M	324 M	384 M	436 M	503 M	342 M	177 M	203 M	218 M	237 M	255 M	664 M	155 M	95.7 M	116 M	113 M	129 M	146 M	141 M	102 M	102 M	102 M	102 M	96.2 M	96.7 M	-	-	78.2 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
664 M	78.2 M	215 M

Total Assets of other stocks in the Biotechnology industry

Issuer	Total Assets	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	2.03 B	-	2.43 %	$ 254 M	Germany
Amgen AMGN	90.6 B	$ 349.77	0.57 %	$ 188 B	USA
Amphastar Pharmaceuticals AMPH	1.63 B	$ 19.23	-1.38 %	$ 899 M	USA
Altimmune ALT	280 M	$ 3.44	2.99 %	$ 303 M	USA
Autolus Therapeutics plc AUTL	783 M	$ 1.4	2.19 %	$ 357 M	Britain
Aytu BioScience AYTU	124 M	$ 2.63	0.77 %	$ 16.5 M	USA
I-Mab IMAB	6.33 B	-	-	$ 866 M	China
Alexion Pharmaceuticals, Inc. ALXN	18.1 B	-	-	$ 40.3 B	USA
Genfit SA GNFT	151 M	-	2.54 %	$ 160 B	France
Biophytis SA BPTS	12 M	-	-13.47 %	$ 169 M	France
Ascendis Pharma A/S ASND	1.3 B	$ 218.06	-1.72 %	$ 5 B	Danmark
Midatech Pharma plc MTP	14.8 M	-	-18.52 %	$ 27.3 M	Britain
EyeGate Pharmaceuticals, Inc. EYEG	15.2 M	-	-1.52 %	$ 24.7 M	USA
Applied Genetic Technologies Corporation AGTC	66.7 M	-	-	$ 26.5 M	USA
ARCA biopharma ABIO	396 M	-	1052.0 %	$ 415 M	USA
Benitec Biopharma BNTC	99.6 M	$ 11.19	1.91 %	$ 461 M	USA
Aeterna Zentaris AEZS	35.1 M	-	5.93 %	$ 314 M	Canada
AgeX Therapeutics AGE	12 M	-	-10.17 %	$ 12.2 K	USA
Acorda Therapeutics ACOR	109 M	-	-24.86 %	$ 820 K	USA
Albireo Pharma ALBO	302 M	-	-0.23 %	$ 916 M	USA
Aileron Therapeutics ALRN	62.2 M	-	10.36 %	$ 9.8 M	USA
Compugen Ltd. CGEN	157 M	$ 2.09	-	$ 195 M	Israel
Acasti Pharma ACST	72 M	-	4.01 %	$ 150 M	Canada
Институт стволовых клеток человека ISKJ	1.51 B	-	-	-	Russia
CollPlant Biotechnologies Ltd. CLGN	18.7 M	$ 0.61	-1.3 %	$ 6.99 M	Israel
Avenue Therapeutics ATXI	2.67 M	-	-52.27 %	$ 4.45 M	USA
Adverum Biotechnologies ADVM	180 M	-	-	$ 86.2 M	USA
Acer Therapeutics ACER	11.6 M	-	2.71 %	$ 14 M	USA
Advaxis ADXS	16.6 M	-	-9.65 %	$ 45.9 M	USA
Cellectis S.A. CLLS	325 M	$ 3.42	2.4 %	$ 116 M	France
Ayala Pharmaceuticals AYLA	7.77 M	-	-	$ 7.46 M	Israel
Cullinan Management CGEM	448 M	$ 12.84	0.78 %	$ 774 M	USA
Atreca BCEL	155 M	-	-11.76 %	$ 5.79 M	USA
BioDelivery Sciences International BDSI	325 M	-	-4.8 %	$ 255 M	USA
BeiGene, Ltd. BGNE	8.19 B	-	0.49 %	$ 251 B	Cayman-islands
Calithera Biosciences CALA	64.8 M	-	-10.95 %	$ 876 K	USA
CorMedix CRMD	826 M	$ 6.42	2.72 %	$ 462 K	USA
Cara Therapeutics CARA	126 M	-	-3.03 %	$ 260 M	USA
ChemoCentryx CCXI	426 M	-	-	$ 3.74 B	USA
Bellerophon Therapeutics BLPH	7.94 M	-	-74.18 %	$ 955 K	USA
Checkpoint Therapeutics CKPT	7.47 M	-	-	$ 169 M	USA
Clovis Oncology CLVS	473 M	-	-7.23 %	$ 13 M	USA
Aeglea BioTherapeutics AGLE	778 M	-	-	$ 1.01 B	USA
CureVac N.V. CVAC	1.16 B	-	-	$ 867 M	Germany
Denali Therapeutics DNLI	1.37 B	$ 21.09	4.56 %	$ 3.47 B	USA
Dyadic International DYAI	8.22 M	$ 0.86	-8.51 %	$ 24.8 M	USA
Akero Therapeutics AKRO	826 M	-	-	$ 3.67 B	USA
Arbutus Biopharma Corporation ABUS	144 M	$ 4.42	4.25 %	$ 734 M	Canada
Akouos AKUS	279 M	-	0.23 %	$ 488 M	USA
AIkido Pharma AIKI	47.1 M	-	1.93 %	$ 17.4 M	USA